Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin

Author:

Barriere S L1,Catlin D H1,Orlando P L1,Noe A1,Frost R W1

Affiliation:

1. Department of Pharmaceutical Services, University of California, Los Angeles 90024.

Abstract

Healthy subjects were given single intravenous doses of ciprofloxacin, azlocillin, and the two drugs simultaneously on separate occasions. High-pressure liquid chromatographic analysis was used to assay the concentrations of both drugs in serum and urine. Pharmacokinetic parameters were calculated by noncompartmental methods. The total body (CL), renal (CLR), and nonrenal (CLNR) clearances; steady-state volume of distribution (Vss); and fractional urinary excretion of ciprofloxacin were all markedly decreased with the simultaneous administration of azlocillin. The disposition of azlocillin was unchanged when it was given with ciprofloxacin compared to when it was given alone. The pharmacokinetic parameters (mean +/- standard deviation) of ciprofloxacin given alone versus in combination with azlocillin were as follows: CL, 52.2 +/- 9.2 versus 33.9 +/- 6.0 liters/h (P less than 0.0005); CLR, 26.5 +/- 4.8 versus 16.2 +/- 4.2 liters/h (P less than 0.0005); CLNR, 25.8 +/- 5.5 versus 17.7 +/- 4.0 liters/h (P less than 0.03); Vss, 224 +/- 30 versus 166 +/- 41 liters (P less than 0.01); fractional urinary excretion, 0.56 +/- 0.06 versus 0.43 +/- 0.04 (P less than 0.002), respectively. This interaction resulted in significantly higher and more prolonged concentrations of ciprofloxacin in serum, which may be beneficial in the treatment of serious gram-negative bacterial infections, but it could also produce greater toxicity or result in more pronounced effects on oxidative drug metabolism of other medications.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference11 articles.

1. Ciprofloxacin, azlocillin, ceftizoxime, and amikacin alone and in combination against gram-negative bacilli in an infected chamber model;Bamberger D. M.;J. Antimicrob. Chemother.,1986

2. The acylampicillins: mezlocillin, piperacillin, and azlocillin;Drusano G. L.;Rev. Infect. Dis.,1984

3. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis;Johnson M.;J. Infect. Dis.,1987

4. Jusko W. J. 1989. Guidelines for collection and analysis of pharmacokinetic data p. 9-54. In W. E. Evans J. J. Schentag and W. J. Jusko (ed.) Applied pharmacokinetics-principles and therapeutic drug monitoring 2nd ed. Applied Therapeutics Inc. San Francisco.

5. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function;Kampf D.;Clin. Pharmacol. Ther.,1984

Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Optimizing Therapeutic Drug Monitoring in Pregnant Women: A Critical Literature Review;Therapeutic Drug Monitoring;2023-01-19

2. Beta-Lactam Antibiotics;Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions;2018

3. Renal Drug Transporters and Drug Interactions;Clinical Pharmacokinetics;2017-02-16

4. Beta-Lactam Antibiotics;Drug Interactions in Infectious Diseases;2011

5. Therapeutic implications of renal anionic drug transporters;Pharmacology & Therapeutics;2010-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3